234,279 Shares in Aquestive Therapeutics, Inc. $AQST Purchased by Simplify Asset Management Inc.

Simplify Asset Management Inc. purchased a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 234,279 shares of the company’s stock, valued at approximately $972,000. Simplify Asset Management Inc. owned 0.19% of Aquestive Therapeutics as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. NewEdge Advisors LLC acquired a new position in Aquestive Therapeutics in the 3rd quarter valued at $28,000. BNP Paribas Financial Markets boosted its position in shares of Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after acquiring an additional 4,134 shares during the period. Modern Wealth Management LLC acquired a new position in shares of Aquestive Therapeutics in the second quarter valued at about $33,000. Elevation Point Wealth Partners LLC bought a new position in Aquestive Therapeutics during the first quarter worth about $42,000. Finally, Kestra Private Wealth Services LLC acquired a new stake in Aquestive Therapeutics in the 3rd quarter worth about $60,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Stock Performance

Aquestive Therapeutics stock opened at $4.18 on Friday. Aquestive Therapeutics, Inc. has a 52 week low of $2.93 and a 52 week high of $7.55. The stock has a market capitalization of $524.46 million, a P/E ratio of -6.85 and a beta of 1.45. The stock has a fifty day moving average of $4.22 and a 200-day moving average of $4.32.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Wednesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. The business had revenue of $14.45 million during the quarter, compared to the consensus estimate of $10.90 million. On average, research analysts forecast that Aquestive Therapeutics, Inc. will post -0.41 earnings per share for the current year.

Insider Activity at Aquestive Therapeutics

In related news, Director Julie Krop sold 25,000 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total transaction of $125,500.00. Following the sale, the director owned 25,000 shares of the company’s stock, valued at $125,500. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Barber sold 8,257 shares of the business’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $4.29, for a total value of $35,422.53. Following the sale, the chief executive officer owned 660,574 shares in the company, valued at $2,833,862.46. This represents a 1.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on AQST. Oppenheimer initiated coverage on shares of Aquestive Therapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $8.00 target price on the stock. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $8.50.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.